Drug Delivery Device for Sinusitis Moves to Phase III Trials

In-Pharmatechnologist is reporting that OptiNose has received a $48.5 million dollar investment to advance their new drug delivery device to phase III trials. The drug is intended for use in delivering medication to the entrance of the sinuses for the treatment of both sinusitis and rhinitis. OptiNose claims current treatments aren't as effective, because they aren't reaching the affected area, which their new device would rectify.Treatment of sinusitis is evolving with new procedures and devices being tested. For those suffering from chronic sinusitis there may be some relief. If you have questions or concerns about sinusitis, contact our office for an appointment.